Toner, Yohana C.
Ghotbi, Adam A.
Naidu, Sonum
Sakurai, Ken
van Leent, Mandy M. T.
Jordan, Stefan
Ordikhani, Farideh
Amadori, Letizia
Sofias, Alexandros Marios
Fisher, Elizabeth L.
Maier, Alexander
Sullivan, Nathaniel
Munitz, Jazz
Senders, Max L.
Mason, Christian
Reiner, Thomas
Soultanidis, Georgios
Tarkin, Jason M.
Rudd, James H. F.
Giannarelli, Chiara
Ochando, Jordi
PĂ©rez-Medina, Carlos
Kjaer, Andreas
Mulder, Willem J. M.
Fayad, Zahi A.
Calcagno, Claudia
Funding for this research was provided by:
NIH/NHLBI (R01 HL135878, R01 HL135878, R01 HL135878)
The Lundbeck Foundation (R251-2017-870)
Institutional Research Training Grant (T32CA078207)
Deutsche Forschungsgemeinschaft (MA7059/1)
Memorial Sloan-Kettering Cancer Center (P30 CA008748)
Wellcome Trust (211100/Z/18/Z)
NIHR Cambridge Biomedical Research Centre
The British Heart Foundation
Higher Education Funding Council for England
Engineering and Physical Sciences Research Council
NIH-NHLBI (R01 HL153712-01)
NIH-NCATS (UH3TR002067)
American Heart Association (20SFRN35210252)
Chan Zuckerberg Initiative (NFL-2020-218415)
Article History
Received: 15 November 2021
Accepted: 22 March 2022
First Online: 13 April 2022
Competing interests
: Andreas Kjaer is an inventor on a patent/holds IPR regarding the use of [<sup>64</sup>Cu]Cu-DOTATATE in neuroendocrine tumor patients. The other authors report no Relationship with Industry and Other Entities. No other potential conflicts of interest relevant to this article exist.